Fredrickson, D., The inheritance of high-density lipoprotein deficiency (Tangier disease), J. Clin. Invest., 43, 228, 1964.
2.
Kimball, O., The treatment of epilepsy with sodium diphenyl-hydantoinate, JAMA, 112, 1244, 1939.
3.
Rateitschak-Plüss, E., Hefti, A., Loertscher, R., and Thiel, G., Initial observation that cyclosporine-A induces gingival enlargement in man, J. Clin. Periodontol., 10, 237, 1983.
4.
Calne, R., White, D., Thiru, S., Evans, D., McMaster, P., Dunn, D., Craddock, G., Pentlow, D., and Rolles, K., Cyclosporine-A in patients receiving renal allografts from cadaver donors, Lancet, 2, 1323, 1978.
5.
Stern, Z. and Levy, M., Nifedipine - a new anti-anginal agent, Harefuah (J. Isr. Med. Assoc.), 10, 494, 1981.
6.
Ramon, Y., Behar, S., Kishon, Y., and Engelberg, I., Gingival hyperplasia caused by nifedipine - a preliminary report, Int. J. Cardiol., 5, 195, 1984.
7.
Lederman, D., Lumerman, H., Reuben, S., and Freedman, P., Gingival hyperplasia associated with nifedipine therapy, Oral Surg., 57, 620, 1984.
8.
Van der Wall, E., Tuinzing, D., and Hiss, J., Gingival hyperplasia: a possible side effect of nifedipine, Ned. Tijdschn. Geneeskd., 128, 1954, 1984.
9.
Lucas, R., Howell, L., and Wall, B., Nifedipine-induced gingival hyperplasia. A histochemical and ultrastructural study, J. Periodontol., 56, 211, 1985.
10.
Shaftic, A., Widdup, L., Abate, M., and Jacknowitz, A., Nifedipine-induced gingival hyperplasia, Drug. Intell. Clin. Pharm., 20, 602, 1986.
11.
Slavin, J. and Taylor, J., Cyclosporine, nifedipine, and gingival hyperplasia, Lancet, 2 (8561), 739, 1987.
12.
Barak, S., Engelberg, I., and Hiss, J., Gingival hyperplasia caused by nifedipine. Histopathologic findings, J. Periodontol., 58, 639, 1987.
13.
Hassell, T., Epilepsy and the Oral Manifestations of Phenytoin Therapy, Basle, Karger, 1981.
14.
Glossmann, H., Ferry, D., Goll, A., Striessnig, J., and Zernig, G., Calcium channels: introduction into their molecular pharmacology, in Cardiovascular Effects of Dihydropridine-Type Calcium Antagonists and Agonists, Fleckenstein, A., Van Breemen, C., Gross, R., and Hoffmeister, F., Eds., Springer Verlag, Berlin, 1985, 113.
15.
Bellemann, P., Ferry, D., Luebbecke, F., and Glossmann, H., [3H]-Nitrendipine, a potent calcium antagonist binds with high affinity to cardiac membranes, Drug Res., 31, 2064, 1981.
16.
Fleckenstein, A., Calcium antagonism in the heart and smooth muscle, in Experimental Facts and Therapeutic Prospects, John Wiley & Sons, New York, 1983.
17.
Ljung, B. and Nordlander, M., Pharmacodynamic properties of felodipine, Drugs, 34(Suppl. 3), 7, 1987.
18.
Guazzi, M., Use of calcium channel blocking agents in the treatment of systemic arterial hypertension, in Calcium Channel Blocking Agents in the Treatment of Cardiovascular Disorders, Stone, P., Ed., Futura, New York, 1983.
19.
Dollery, C., Hypertension and new antihypertensive drugs: clinical perspectives, Fed. Proc., 42, 207, 1983.
20.
Guazzi, M.D., Olivari, M., and Polese, A., Nifedipine, a new antihypertensive with rapid action, Clin. Pharmacol. Ther., 22, 528, 1977.
21.
Guazzi, M.D., DeCesare, N., Galli, C., Tamborini, G., and Salvioni, A., Nitrendipine vs. long-acting nifedipine in mild, moderate and severe hypertension, Angiology, 37, 508, 1986.
22.
Guazzi, M., DeCesare, N., and Galli, C., Calcium channel blockade with nifedipine and angiotensin-converting enzyme inhibition with captopril in the therapy of patients with severe primary hypertension, Circulation, 70, 279, 1984.
23.
Bencini, P., Crosti, C., Sala, F. et al., gingival hyperplasia by nifedipine - report of a case, Acta Derm. Venereol. (Stockholm), 65, 362, 1985.
24.
Fletcher, P., Nifedipine (Procardia) and gingival hyperplasia: a new diagnostic concern for practitioners, Bull. Ninth Dist. Dent. Soc., 70, 52, 1986.
25.
Lainson, P., Gingival overgrowth in a patient treated with nifedipine (Procardia), Periodont. Case Rep., 8, 64, 1986.
26.
Heijl, L. and Sundin, Y., Nitrendipine-induced gingival overgrowth in dogs, J. Dent. Res., 66, 282, 1987.
27.
Hassell, T., Page, R., and Lindhe, J., Histologic evidence for impaired growth in diphenylhydantoin overgrowth in man, Arch. Oral Biol., 23, 381, 1978.
28.
Hassell, T., Roebuck, S., Page, R., and Wray, S., Quantitative histopathologic assessment of developing phenytoin-induced gingival overgrowth in the cat, J. Clin. Periodontol., 9, 365, 1982.
29.
Hassell, T. and Sobhani, S., Effects of dihydropyridines on connective tissue cells in vitro, J. Dent. Res., 66, 282, 1987.
30.
Socransky, S., Haffajee, A., Goodson, J., and Lindhe, J., New concepts of destructive periodontal disease, J. Clin. Periodontol., 11, 21, 1984.
31.
Borel, J.F., The history of cyclosporine-A and its significance, in Cyclosporine-A, White, D. J. G., Ed., Elsevier, Amsterdam, 1982, 5.
32.
Kahan, B., Ed., Proceedings of the First International Congress on Cyclosporine, Houston, TX, 1983, Grune and Stratton, Philadelphia, 1984.
33.
Proceedings of the Second International Congress on Cyclosporine, Washington, D.C., 1988, Grune and Stratton, Philadelphia, 1988.
34.
Borel, J., Feurer, C., Gubler, H., and Staehelin, H., Biological effects of cyclosporine-A: a new antilymphocytic agent, Agents Actions, 6, 468, 1976.
35.
Petcher, T., Weber, H., and Riiegger, A., Crystal and molecular structure of an iododerivative of the cyclic undecapeptide cyclosporine-A, Helv. Chim. Acta, 59, 1480, 1976.
36.
Rüegger, A., Kuhn, M., Liechti, H., Loosli, H., Huguenin, R., Quiquerez, C., and von Wartburg, A., Cyclosporine-A: ein immunosuppressiv wirksamer Peptidmetabolit aus Trichoderma polysporum (Link ex Pers.) Rifai, Helv. Chim. Acta, 59, 1075, 1976.
37.
Calne, R., White, D., Rolles, K., Smith, D., and Herbertson, B., Prolonged survival of pig orthotopic heart grafts treated with cyclosporine-A, Lancet, 1, 1183, 1978.
38.
Calne, R. and White, D., Cyclosporine-A - a powerful immunosuppressant in dogs with renal allografts, IRCS Med. Sci., 5, 595, 1977.
39.
Powles, R., Barrett, A., Clink, H., Kay, H., Sloane, J., and McElwain, T., Cyclosporine-A for treatment of graft-vs.-host disease in man, Lancet, 2, 1327, 1978.
40.
Borel, J., Feurer, C., Magnee, C., and Staehelin, H., Effects of the new anti-lymphocytic peptide cyclosporine-A in animals, Immunology, 32, 1017, 1977.
41.
Kostakis, A., White, D., and Caine, R., Prolongation of the rat heart allograft survival by cyclosporine-A, IRCS Med. Sci., 5, 280, 1977.
42.
Bailey, L.L., Nehlsen-Cannarella, S.L., Concepcion, W., and Jolley, W.B., Baboon-to-human cardiac xenotransplantation in a Neonate, JAMA, 254, 3321, 1985.
43.
Wenger, R., Chemistry of cyclosporine, in Cyclosporine-A, White, D., Ed., Elsevier, Amsterdam, 1982, 19.
44.
Lemaire, M., Distribution and binding to blood components. Unpublished document (Sandoz Ltd., Basle) cited in Beveridge, T., Pharmacokinetics and Metabolism of Cyclosporine-A, in Cyclosporine-A, White, D., Ed., Elsevier, Amsterdam, 1982, 35.
45.
Beveridge, T., Pharmacokinetics and metabolism of cyclosporine-A, in Cyclosporine-A, White, D., Ed., Elsevier, Amsterdam, 1982, 35.
46.
Hess, A., Tutschka, P., and Santos, G., The effect of cyclosporine-A on T-lymphocyte subpopulations, in Cyclosporine-A, White, D., Ed., Elsevier, Amsterdam, 1982, 209.
47.
Maurer, G. and Schreier, E., Pharmacokinetic studies with 3H-OL 26-400 in rat, dog, monkey and man and preliminary biotransformation studies in rabbit, dog and man, Unpublished Sandoz Co. document, cited in Beveridge, T., Pharmacokinetics and Metabolism of Cyclosporine-A, in Cyclosporine-A, White, D., Ed., Elsevier, Amsterdam, 1982, 40.
48.
Kahan, B. and Grevel, J., Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy, Transplantation, 46, 631, 1988.
49.
Zylber-Katz, E. and Granit, L., Cyclosporine blood concentration determined by different assay methods in heart transplant patients, Drug Monitor., 11, 592, 1989.
50.
Kunzendorf, U., Brockmöller, J., Jochimsen, F., Keller, F., Roots, I., Walz, G., and Offermann, G., Cyclosporine drug monitoring: comparison of four immunoassays and HPLC, Klin. Wochenschr., 67, 438, 1989.
51.
Johnston, A., Marsden, J.T., and Holt, D.W., The United Kingdom cyclosporine quality assessment scheme, Therap. Drug Monitor., 8, 200, 1986.
52.
Plebani, M., Sciacovelli, L., and Burlina, A., Importance of control materials in quality assessment of cyclosporine determination, Therap. Drug Monitor., 10, 361, 1988.
53.
Thomson, A.W. and Webster, L.M., The influence of Cyclosporine A on cell-mediated immunity, Clin. Exp. Immunol., 71, 369, 1988.
54.
Granelli-Piperno, H., Lymphokine gene expression in vivo is inhibited by Cyclosporin A, J. Exp. Med., 71, 533, 1990.
55.
Borel, D.F. and Ryffel, B., The mechanism of action of cyclosporine: a continuing puzzle, in Cyclosporine in Autoimmune Diseases, Schindler, R., Ed., Springer, Berlin, 1985, 24.
56.
Ryffel, B., Aktivierung von humanen T-lymphozyten und ihre Hemmung durch Ciclosporin, Habilitationsschrift, University of Basle, 1986.
57.
Colombani, P.M., Robb, A., and Hess, A.D., Cyclosporin A binding to calmodulin: a possible site of action on T lymphocytes, Science, 228, 337, 1985.
58.
Handschuhmacher, R.E., Harding, M.W., Rice, J., and Drugge, R.J., Cyclophilin: a specific cytosolic binding protein for cyclosporine A, Science, 226, 544, 1984.
59.
Hess, A.D. and Colombani, P.M., Mechanism of action of cyclosporine: a unifying hypothesis, Adv. Exp. Med. Biol., 213, 309, 1987.
60.
Le Grue, S.J., Turner, R., Weisbrodt, N., and Dedman, J.R., Does the binding of cyclosporine to calmodulin result in immunosuppression?, Science, 234, 68, 1986.
61.
Hait, W.N., Harding, M.W., and Handschuhmacher, R.E., Calmodulin, cyclophilin and CsA, Science, 233, 987, 1986.
62.
Yoshimura, N., Oha, T., and Clark, S.C., The inhibition of interleukin 2 (IL-2) gene expression at the level of messenger RNA by in vivo cyclosporine treatment in kidney transplant recipients, Transplant Proc., 19, 3510, 1987.
63.
Kaufman, Y., Chang, A., Robb, R., and Rosenberg, S., Mechanism of action of cyclosporine-A: inhibition of lymphokine secretion studied with antigen-stimulated T cell hybridomas, J. Immunol., 133, 3107, 1984.
64.
Gelfand, E., Cheung, R., and Mill, G., The cyclosporines inhibit lymphocyte activation at more than one site, J. Immunol., 138, 1115, 1987.
65.
Bunjes, D., Hardt, C., Röllinghoff, H., and Wagner, H., Cyclosporine-A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin I and interleukin 2, Eur. J. Immunol., 11, 657, 1981.
66.
Hess, A., Colombani, A., Donnenberg, A., and Ryffel, B., Binding of dansylated cyclosporine discriminates functional T lymphocyte subsets, Transplant. Proc., XVII, 1419, 1985.
67.
Billingham, M., Diagnosis of cardiac rejection by endomyocardial biopsy, Heart Transplant., 1, 25, 1981.
68.
Farnsworth, A., Hall, B., Ng, A., Duggin, G., Horrath, I., Shiel, A., and Tiller, D., Renal biopsy morphology in renal transplantation, Am. J. Surg. Pathol., 8, 243, 1984.
69.
Janin-Mercier, A., Valade, S., Boccon-Gibbod, L., D'Agay, M., Bourges, M., Devergie, A., and Gluckman, E., Lesions pulmonaires apres grette de moelle osseuse: Etude de 35 cas, Ann. Pathol., 5, 183, 1985.
70.
Adams, D. and Davies, G., Gingival hyperplasia induced by cyclosporine-A, Br. Dent. J., 157, 89, 1984.
71.
Bennet, J. and Christian, J., Cyclosporine-induced gingival hyperplasia: case report and literature review, J. Am. Dent. Assoc., 111, 272, 1985.
72.
Rostock, M., Fry, R., and Turner, J., Severe gingival overgrowth associated with cyclosporine therapy, J. Periodontol., 57, 294, 1986.
73.
Schulz, A., Lange, D., Hassell, T., Lison, A., and Stone, C., Ciclosporin-induzierte Gingivahyperplasie bei Patienten mit Nierentransplantaten, Dtsch. Z. Zeitschr., in press, 1990.
74.
Hassell, T., O'Donnell, J., Pearlman, J., Tesini, D., Murphy, T., and Best, H., Phenytoin-induced gingival overgrowth in institutionalized epileptics, J. Clin. Periodontol., 11, 242, 1984.
75.
Phillips, B., Eshenaur, A., Schulz, A., Vock, P., Shen, S., Romberg, E., and Hassell, T., Incidence of cyclosporine-induced gingival overgrowth in renal transplant patients, J. Dent. Res., 67 (Abstr.), 332, 1988.
76.
Friskopp, J. and Klintmalm, G., Gingival enlargement. A comparison between cyclosporine and azathioprine treated renal allograft recipients, Swed. Dent. J., 10, 85, 1986.
77.
Seymour, R.A., Smith, D.G., and Rogers, R., The comparative effects of azathioprine and cyclosporine on some gingival health parameters of renal transplant patients, a longitudinal study, J. Clin. Periodontol., 14, 610, 1987.
78.
McGaw, T., Lam, S., and Coates, J., Cyclosporine-induced gingival overgrowth: correlation with dental plaque scores, gingivitis scores, and cyclosporine levels in serum and saliva, Oral Surg. Oral Med. Oral Pathol., 64, 293, 1987.
79.
Daley, T.D., Wysocki, G.P., and Day, C., Clinical and pharmacological correlations in cyclosporine-induced gingival hyperplasia, Oral Surg. Oral Med. Oral Pathol., 62, 417, 1986.
80.
Tyldesley, W.R. and Rotter, E., Gingival hyperplasia induced by cyclosporine-A, Br. Dent. J., 157, 305, 1984.
81.
Tejani, A., Butt, K.M., Khawar, M.R., Hong, J.H., Fusi, M., and Pomrantz, A., Cyclosporine experience in renal transplantation in children, Mt. Sinai J. Med., 54, 467, 1987.
82.
Schuller, P., Freedman, H., and Lewis, D., Periodontal status of renal transplant patients receiving immunosuppressive therapy, J. Periodontol., 44, 167, 1973.
83.
Oshrain, H.I., Telsey, B., and Mandel, I.D., A longitudinal study of periodontal disease in patients with reduced immunocapacity, J. Periodontol., 54, 151, 1983.
84.
Tollefsen, T. and Johansen, J., The periodontal status of prospective and renal transplant patients. Comparisons with systemically healthy subjects, J. Periodontol. Res., 20, 220, 1985.
85.
Kardachi, B.J. and Newcomb, G.M., A clinical study of gingival inflammation in renal transplant recipients taking immunosuppressant drugs, J. Periodontol., 49, 307, 1978.
86.
Been, V. and Engel, D., The effects of immunosuppressive drugs on periodontal inflammation in human renal allograft patients, J. Periodontol., 53, 245, 1982.
87.
Guggenheim, B., Gaegauf-Zollinger, R., Hefti, A., and Burckhardt, J.J., The effect of cyclosporine-A on periodontal disease in rats monoassociated with Actinomyces viscosus Nyl, J. Periodontol. Res., 16, 26, 1981.
88.
Stone, C., Eshenaur, A., and Hassell, T., Gingival enlargement in cyclosporine-treated multiple sclerosis patients, J. Dent. Res., 68 (Abstr.), 285, 1989.
89.
Palestine, A.G., Nussenblatt, R.B., and Chan, C.C., Side effects of systemic cyclosporine in patients not undergoing transplantation, Am. J. Med., 77, 652, 1984.
90.
Karmi, S., DePalma, R., Bosch, J., Dosa, S., and Mitchell, A., An update on the use of low-dose maintenance cyclosporine-A therapy after renal transplantation, Transplant. Proc., 20, 110, 1988.
91.
Seibel, W., Yahia, N., McCleary, L., Lesko, L., and Hassell, T., Cyclosporine-induced gingival overgrowth in Beagle dogs, J. Oral Pathol. Med., 18, 240, 1989.
92.
Phillips, B., Shen, S., Lesko, L., Emm, T., and Hassell, T., Levels of cyclosporine-A in human parotid fluid and whole saliva, J. Dent. Res., 65 (Abstr.), 353, 1986.
93.
Steinberg, A., Phenytoin penetration through sulcular tissues and its possible relationship to phenytoin-induced gingival overgrowth, in Phenytoin-Induced Teratology and Gingival Pathology, Hassell, T., Johnston, M., and Dudley, K., Eds., Raven Press, New York, 1980, 179.
94.
Kohase, M., May, L.T., Tamm, I., Vilcek, J., and Sehgal, P., A cytokine network in human diploid fibroblasts: interactions of β-interferon, tumor necrosis factor, platelet-derived growth factors, and interleukin-1, Mol. Cell. Biol., 7, 273, 1987.
95.
Amento, E.P., Bhau, A.K., McCullag, K.G., and Krane, S.M., Influences of gamma interferon on synovial fibroblast-like cells, J. Clin. Invest., 76, 837, 1985.
96.
Schmidt, J.A., Oliver, C.N., Lepe-Zuniga, Z.L., Green, I., and Gery, I., Silica-stimulated monocytes release fibroblast proliferation factors identical to interleukin-1, J. Clin. Invest., 73, 1462, 1984.
97.
Bronson, R.E., Bertolami, C.N., and Siebert, E.P., Modulation of fibroblast growth and glycosaminoglycan synthesis by interleukin-1, Coll. Rel. Res., 7, 323, 1987.
98.
Saklatrala, J., Pilsworth, L.M.C., Sarsfield, S.J., Gavrilovic, J., and Heath, J.K., Pig catabolin is a form of interleukin-1. Cartilage and bone fibroblasts make prostaglandin and collagenase, and thymocyte proliferation is augmented in response to one protein, Biochem. J., 224,461, 1984.
99.
Baum, B.J., Moss, J., Brent, S.D., and Crystal, R.G., Association in normal human fibroblasts of elevated levels of adenosine 3:5 monophosphate with a selective decrease in collagen production, J. Biol. Chem., 253, 3391, 1978.
100.
Baum, B., Moss, J., Brent, S., and Crystal, R., Effect of cyclic AMP on the intracellular degradation of newly synthesized collagen, J. Biol. Chem., 255, 2843, 1980.
101.
Hata, R., Sunada, H., Arai, K., Sato, T., Ninomiya, Y., Nagai, Y., and Senoo, H., Regulation of collagen metabolism and cell growth by epidermal growth factor and ascorbate in cultured human skin fibroblasts, Eur. J. Biochem., 173, 261, 1988.
102.
Wysocki, G.P., Gretzinger, H.A., Laupacis, A., Ulan, R.A., and Stiller, C.R., Fibrous hyperplasia of the gingiva. A side effect of cyclosporine-A therapy, Oral Surg., 55, 274, 1983.
103.
Deliliers, G.L., Santoro, F., Polli, N., Bruno, E., Fumagalli, L., and Risciotti, E., Light and electron microscopic study of cyclosporine-A-induced gingival hyperplasia, J. Periodontol., 57, 771, 1986.
104.
Pisanty, S., Shoshan, S., Chajek, T., Maftsir, G., Sacks, B., and BenEzra, D., The effect of cyclosporine-A (CsA) treatment on gingival tissue of patients with Behcet's disease, J. Periodontol., 59, 599, 1988.
105.
Hall, B.K. and Squier, C.A., Ultrastructural quantitation of connective tissue changes in phenytoin-induced gingival overgrowth in the ferret, J. Dent. Res., 61, 942, 1982.
106.
Yamasaki, A., Rose, G.G., Pinero, G.J., and Mahan, C.J., Ultrastructure of fibroblasts in cyclosporin-A-induced gingival hyperplasia, J. Oral. Pathol., 16, 129, 1987.
107.
Ryffel, B., Donatsch, P., Madorin, M., Matter, B.E., Ruttimann, G., Schon, H., Stoll, R., and Wilson, J., Toxicological evaluation of cyclosporine-A, Arch. Toxicol., 53, 107, 1983.
108.
Seibel, W., Sundberg, J., Lesko, L., Sauk, J., McCleary, L., and Hassell, T., Cutaneous papillomatous hyperplasia in cyclosporine-A treated beagles, J. Invest. Dermatol., 93, 224, 1989.
109.
Meyer, R., Zur Histologie Cyclosporin-A induzierte Gingivalasionen, Dissertation, University of Basle, 1984.
110.
Harper, J., Kendra, J., Desai, S., Staughton, R., Barrett, A., and Hobbs, J., Dermatological aspects of the use of cyclosporine-A for prophylaxis of graftvs.-host disease, Br. J. Dermatol., 110, 469, 1984.
111.
Bencini, P., Montagnio, G., Sala, F., DeVecchio, A., Crosti, C., and Tarantino, A., Cutaneous lesions in 67 cyclosporine-treated renal transplant recipients, Dermatologica, 172, 24, 1986.
112.
Ellis, C., Gorsulowsky, D., Hamilton, T., Billings, J., Brown, M., Headington, J., Cooper, K., Baadsgaard, O., Duell, E., and Annesley, T., Cyclosporine improves psoriasis in a double-blind study, JAMA, 256, 3110, 1986.
113.
Wentzell, J., Baughman, R., O'Connor, G., and Bernier, G., Cyclosporine in the treatment of psoriasis, Arch. Dermatol., 123, 163, 1987.
114.
Frances, C., Boisnic, S., Etienne, S., and Szpirglas, H., Effect of the local application of cyclosporine-A on chronic erosive lichen planus of the oral cavity, Dermatologica, 177, 194, 1988.
115.
Nickoloff, B., Fisher, G., Mitra, R., and Voorhees, J., Additive antiproliferative effect of Cyclosporine-A and gamma interferon, J. Cutan. Pathol., 14, 363, 1987.
116.
Urabe, M., Kanitakis, J., Viac, J., and Thivolet, J., Cyclosporine-A inhibits directly in vivo keratinocyte proliferation of living human skin, J. Invest. Dermatology, 92, 755, 1989.
117.
Seibel, W., Yahia, N., Stone, C., and Hassell, T., Synthetic activity of cultured gingival fibroblasts from normal and cyclosporine-A-treated Beagles, J. Clin. Periodontol., submitted.
118.
Yahia, N., Seibel, W., McCleary, L., Lesko, L., and Hassell, T., Effect of toothbrushing on cyclosporine-induced gingival overgrowth in Beagles, J. Dent. Res., 67 (Abstr.), 332, 1988.
119.
Coley, C., Jarvis, K., and Hassell, T., Effect of cyclosporine-A on human gingival fibroblasts in vitro, J. Dent. Res., 65, 353, 1986.
120.
Zebrowski, E., Singer, D., and Brunka, J., Cyclosporine-A, nifedipine and phenytoin: comparative effects on gingival fibroblast metabolism, J. Dent. Res., 65, 331, 1986.
121.
Sobhani, S., Hassell, T., and Stone, C., Patient age and susceptibility to cyclosporine gingival enlargement: in vitro study, J. Dent. Res., 68 (Abstr.), 416, 1989.
122.
Hassell, T., Romberg, E., Sobhani, S., Lesko, L., and Douglas, R., Lymphocyte-mediated effects of cyclosporine on human fibroblasts, Transplant. Proc., 20, 993, 1988.
123.
Bartold, P., Regulation of human gingival fibroblast growth and synthetic activity by cyclosporine-A in vitro, J. Periodontol. Res., 24, 314, 1989.
124.
Kimball, O.P., The treatment of epilepsy with sodium diphenylhydantoinate, JAMA, 112, 1244, 1939.
125.
Hammond, W. A., Ed., Clinical Lectures on Diseases of the Nervous System, T.M.B. Cross, New York, 1874.
126.
Esterberg, H. and White, P., Sodium dilantin gingival hyperplasia, J. Am. Dent. Assoc., 32, 16, 1945.
127.
Dreifuss, F.E., Foreword, in Hassell, T. M., Epilepsy and the Oral Manifestations of Phenytoin Therapy, Karger, Basle, 1981.
128.
Hassell, T., Johnston, M., and Dudley, K., Eds., Phenytoin-Induced Teratology and Gingival Pathology, Raven Press, New York, 1980.
129.
Addy, V., McElnay, J., Eyre, D., Campbell, N., and D'Arcy, P., Risk factors in phenytoin-induced gingival overgrowth, J. Periodontol., 54, 373, 1983.
130.
Dahllof, G. and Modeer, T., The effect of a plaque control program on the development of phenytoin-induced gingival overgrowth, a 2-year longitudinal study, J. Clin. Periodontol., 13, 845, 1986.
131.
Hassell, T., O'Donnell, J., Pearlman, J., Tesini, D., Best, H., and Murphy, T., Phenytoin induced gingival overgrowth in institutionalized epileptics, J. Clin. Periodontol., 11, 242, 1984.
132.
Palquist, R., Borga, O., Rane, A., Walsh, Z., and Sjoqvist, F., Enhanced plasma protein binding of phenytoin in patients on valproic acid, Br. J. Clin. Pharmacol., 8, 547, 1979.
133.
Maguire, J., Greenwood, R., Lewis, D., and Hassell, T., Phenytoin-induced gingival overgrowth incidence is dependent upon co-medication, J. Dent. Res., 65, 249, 1986.
134.
Steinberg, S. and Steinberg, A., Phenytoin-induced gingival overgrowth in severely retarded children, J. Periodontol., 53,429, 1982.
135.
O'Neil, T. and Figures, K., The effects of chlorhexidine and mechanical methods of plaque control on the recurrence of gingival hyperplasia in young patients taking phenytoin, Br. Dent. J., 152, 130, 1982.
136.
Modeer, T. and Dahllof, G., Development of phenytoin-induced gingival overgrowth in non-institutionalized epileptic children subjected to different plaque control programs, Acta Odontol. Scand., 45, 81, 1987.
137.
Vogel, R., Gingival hyperplasia and folic acid dificiency from anticonvulsant therapy: a theoretical relationship, J. Theor. Biol., 67, 269, 1977.
138.
Vogel, R., Relationship of folic acid to phenytoin induced gingival overgrowth, in Phenytoin-Induced Teratology and Gingival Pathology, Hassell, T., Johnston, M., and Dudley, K., Eds., Raven Press, New York, 1980, 163.
139.
Inoue, F. and Harrison, J., Folic acid and phenytoin hyperplasia, Lancet, 2, 86, 1981.
140.
Williams, C., Poppell, T., Brock, D., and Low, S., Phenytoin induced gingival overgrowth: effect of folic acid supplementation, Clin. Res., 35, 61, 1987.
141.
Jensen, O. and Olsen, O., Folic acid and anticonvulsive drugs, Arch. Neurol., 21, 208, 1969.
142.
Dreizen, S., Levy, B., and Bernick, S., Studies on the biology of the periodontium of marmosets. VII. The effect of folic acid deficiency on the marmoset oral mucosa, J. Dent. Res., 49, 616, 1970.
143.
Drew, H., Vogel, R., Molofsky, W., Baker, H., and Frank, O., Effect of folate on phenytoin hyperplasia, J. Clin. Periodontol., 14, 350, 1987.
144.
Poppell, T., Keeling, S., Collins, J., and Hassell, T., Effect of folic acid on recurrence of phenytoin-induced gingival overgrowth following gingivectomy, J. Clin. Periodontol., submitted.
145.
Hassell, T. and Page, R., The major metabolite of phenytoin (Dilantin) induces gingival overgrowth in cats, J. Periodontol. Res., 13, 280, 1978.
146.
Cockey, G., Boughman, J., Harris, E., and Hassell, T., Genetic control of variation in human gingival fibroblast proliferation rate, In Vitro Cell. Devel. Biol., 25, 255, 1989.
147.
Javed, T., Sitterly, K., Higerd, T., and Miller, C., Bacteriologic study of dental plaque of Dilantin hyperplasia, J. Dent. Res., 59, 485, 1980.
148.
Staple, P., Reed, M., Mashimo, P., Sedransk, N., and Umemoto, T., Diphenylhydantoin gingival hyperplasia in Macaca arctoides: prevention by inhibition of dental plaque deposition, J. Periodontol., 49, 310, 1978.
149.
Smith, Q., Wilson, M., Germaine, G., and Pihlström, B., Microbial flora and clinical parameters in phenytoin associated gingival overgrowth, J. Periodontol. Res., 18, 56, 1983.
150.
Norris, J. and Cunliffe, W., Phenytoin-induced gum hypertrophy improved by isotretinoin, Int. J. Dermatol., 26, 602, 1987.
151.
Hein, R., Mensing, M., and Muller, P., Effect of vitamin A and its derivatives on collagen production and chemotactic response of fibroblasts, Br. J. Dermatol., 111, 37, 1984.
152.
Bauer, E., Seltzer, J., and Eisen, A., Inhibition of collagen degradative enzymes by retinoic acid in vitro, J. Am. Acad. Dermatol., 6, 603, 1982.
153.
Staple, P., Reed, M., and Mashimo, P., Diphenylhydantoin gingival hyperplasia in Macaca arctoides: a new human model, J. Periodontol., 48, 325, 1977.
154.
Aarli, J., Phenytoin-induced depression of salivary IgA and gingival hyperplasia, Epilepsia, 17, 283, 1976.
155.
Ishikawa, J., Studies of gingival hyperplasia associated with sodium diphenylhydantoin therapy. II. Experimental study of dilantin gingival hyperplasia in cats, Nihon Hozon Shikaguku Zasshi, 2, 169, 1959.
156.
Hassell, T. and Cooper, C., Phenytoin-induced gingival overgrowth in a mongrel cat model, in Phenytoin-Induced Teratology and Gingival Pathology, Hassell, T., Johnston, M., and Dudley, K., Eds., Raven Press, New York, 1980, 147.
157.
Hassell, T., Roebuck, S., Page, R., and Wray, S., Quantitative histopathologic assessment of developing phenytoin-induced gingival overgrowth in the cat, J. Clin. Periodontol., 9, 365, 1982.
158.
Motulsky, A., Pharmacogenetics, Prog. Med. Genet., 3,49, 1964.
159.
Boughman, J., Cockey, G., and Hassell, T., Pedigree analysis of phenytoin response in mongrel cats: a possible genetic model for phenytoin sensitivity in humans, J. Dent. Res., 65 (Abstr.), 353, 1986.
160.
Taylor, F., Hassell, T., DeBuysscher, E., and Leslie, G., Effect of Phenytoin upon salivary IgA secretion in the cat, J. Dent. Res., 62, 653, 1983.
161.
Smith, Q., Hamilton, M., Biros, M., and Pihlstrom, B., Salivary and plasma IgG of seizure subjects receiving phenytoin, Epilepsia, 20, 17, 1979.
162.
Bernstein, A. and Hassell, T., Morphometric analysis of phenytoin-enlarged human gingiva at the level of ultrastructure, J. Dent. Res., 66, 235, 1987.
163.
Hassell, T., Page, R., Narayanan, A., and Cooper, C., Diphenylhydantoin (Dilantin) gingival hyperplasia: drug-induced abnormality of connective tissue, Proc. Natl. Acad. Sci. U.S.A., 73, 2909, 1976.
164.
Hassell, T., Stimulation and inhibition of fibroblast subpopulations by phenytoin and phenytoin metabolites: pathogenetic role in gingival enlargement, Pediat. Dent., 3, 137, 1981.
165.
Narayanan, A., Meyers, D., and Page, R., Regulation of collagen production in fibroblasts cultured from normal and phenytoin-induced hyperplastic human gingiva, J. Periodontol. Res., 23, 118, 1988.
166.
Uitto, J., Perejda, A., and Abergel, R., Altered steady-state ratio of type I/III procollagen mRNAs correlates with selectively increased type I procollagen biosynthesis in cultured keloid fibroblasts, Proc. Natl. Acad. Sci. U.S.A., 82, 5935, 1985.
167.
Hurum, S., Sodek, J., and Aubin, J., Synthesis of collagen, collagenase and collagenase inhibitors by cloned human gingival fibroblasts and the effect of concanavalin A, Biochem. Biophys. Res. Commun., 107, 357, 1982.
168.
Hassell, T. and Stanek, E., Evidence that healthy human gingiva contains functionally heterogeneous fibroblast subpopulations, Arch. Oral Biol., 28, 617, 1983.
169.
Hassell, T., Provenza, D., and Foster, R., Synthetic activities of mass cultures and clones of human gingival fibroblasts, Experientia, 42, 66, 1986.
170.
Smith, J. and Whitney, R., Intraclonal variation in proliferative potential of human diploid fibroblasts: stochastic mechanism for cellular aging, Science, 207, 82, 1980.
171.
Hassell, T. and Gilbert, G., Phenytoin sensitivity of fibroblasts as the basis for susceptibility to gingival enlargement, Am. J. Pathol., 112, 218, 1983.
172.
Foster, R. and Hassell, T., Response of single-cell clones of human gingival fibroblasts to phenytoin in vitro, J. Dent. Res., 64, 298, 1985.
173.
Buchanan, J., Cuchens, M., Hassell, T., Ellis, T., and Phipps, L., Human gingival fibroblast subpopulations sorted on the basis of phenytoin responsiveness, J. Dent. Res., 67, 336, 1988.
174.
Modeer, T., Dahllof, G., and Otteskog, P., Potentiation of fibroblast spreading by extracellular matrix from fibroblasts derived from phenytoin-induced gingival overgrowth, Acta Odont. Scand., 46, 101, 1988.
175.
Narayanan, A. and Hassell, T., Characterization of collagens in phenytoin-enlarged gingiva, Coll. Rel. Res., 5, 513, 1985.
176.
Kantor, M. and Hassell, T., Increased accumulation of sulfated glycosaminoglycans in cultures of human fibroblasts from phenytoin-induced gingival overgrowth, J. Dent. Res., 62, 383, 1983.
177.
Dahllof, G., Modeer, T., Reinholt, F., Wikstrom, N., and Hjerpe, A., Proteoglycans and glycosaminoglycans in phenytoin induced gingival overgrowth, J. Periodontol. Res., 21, 13, 1986.
178.
Dahllof, G. and Hjerpe, A., Synthesis of sulfated glycosaminoglycans by human gingival fibroblasts from phenytoin-induced gingival overgrowth, J. Dent. Res., 65, 250, 1987.
179.
Obrink, B. and Sundelof, L., Light scattering in the study of associating macromolecules. The binding of glycosaminoglycans to collagen, Eur. J. Biochem., 37, 226, 1973.
180.
Toole, B. and Lowther, D., The effect of chondroitin sulfate-protein on the formation of collagen fibril in vitro, Biochem. J., 109, 857, 1968.
181.
Vogel, K. and Heinegard, D., Proteoglycans of bovine fibrous tendon and their interactions with tendon collagen in vitro, Proc. 7th Int. Symp. Glycoconjugates, Lund-Ronneby, July 17-23, 1983, 830.
182.
Hassell, T., Evidence for production of an inactive collagenase by fibroblasts from phenytoin-enlarged human gingivae, J. Oral Pathol., 11, 310, 1982.
183.
Goultshin, J. and Shoshan, J., Inhibition of collagen breakdown by diphenylhydantoin, Biochim. Biophys. Acta, 631, 188, 1980.
184.
Cockey, G., Maguire, J., Hassell, T., and Provenza, D., Effect of the methylcatechol metabolite of phenytoin on human gingival fibroblasts, J. Dent. Res., 65, 353, 1986.
185.
Jarvis, K. and Hassell, T., Response of active vs. quiescent fibroblasts to phenytoin, J. Dent. Res., 63, 270, 1984.
186.
Clark, J., Starcher, B., and Uitto, J., Bleomycininduced synthesis of type I procollagen in human lung and skin fibroblasts in culture, Biochim. Biophys. Acta, 631, 359, 1980.
187.
Christian, J. and Norton, J., A proposed test of the difference between the means of monozygotic and dizygotic twins, Acta Genet. Med. Gemellol., 26, 49, 1977.
188.
Cockey, G., Boughman, J., and Hassell, T., Genetic regulation of drug-induced connective tissue disorders: an in vitro model, In Vitro, 23, 23A, 1987.
189.
Cockey, G., Boughman, J., and Hassell, T., Phenytoin response of gingival fibroblasts from human twins, J. Dent. Res., 66, 320, 1987.
190.
Spielberg, S., In vitro assessment of pharmacogenetic susceptibility to toxic drug metabolites in humans, Fed. Proc., 43, 2308, 1984.
Tipton, D. and Dabbous, M., Dose-dependent collagenolytic response profiles of gingival fibroblasts to cyclosporine, J. Dent. Res., 68 (Abstr.), 361, 1989.
193.
Hassell, T., Evidence that cyclosporine, phenytoin and dihydropyridines elicit overgrowth by different mechanisms, J. Dent. Res., 69 (Abstr.), 164, 1990.
194.
Ljung, personal communication, 1985.
195.
Heijl et al., personal communication, 1987.
196.
Tipton and Dabbons, Dose-dependent collagenolytic response profiles in gingival fibroblasts to cyclosporine, J. Dent. Res., 68 (Abstr.), 361, 1989.
197.
Fan and Scott, Cyclosporine effects on gingival fibroblasts in vitro, J. Dent. Res., 68 (Abstr.), 288, 1989.
198.
Burtner, Low, and Hassell, unpublished observations, 1989.
